Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.


Over the last 20 years, median survival for patients with metastatic colorectal cancer (CRC) has remarkably improved from about 12 to over 30 months, mainly because of the development of new agents and patient selection using predictive biomarkers. However, the identification of the most effective treatment for an individual patient is still a challenge… (More)
DOI: 10.1007/s13193-016-0543-z